JPH07508648A - ワクチンとしての即時型ｈｓｖ−２ウイルスタンパク質ｉｃｐ２７ - Google Patents

ワクチンとしての即時型ｈｓｖ−２ウイルスタンパク質ｉｃｐ２７

Info

Publication number
JPH07508648A
JPH07508648A JP6502006A JP50200694A JPH07508648A JP H07508648 A JPH07508648 A JP H07508648A JP 6502006 A JP6502006 A JP 6502006A JP 50200694 A JP50200694 A JP 50200694A JP H07508648 A JPH07508648 A JP H07508648A
Authority
JP
Japan
Prior art keywords
protein
cells
hsv
icp27
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP6502006A
Other languages
English (en)
Japanese (ja)
Inventor
スラウィ，モンセフ
パラ，ピエトロ
クソコ，マルグリット
Original Assignee
スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム）
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） filed Critical スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム）
Publication of JPH07508648A publication Critical patent/JPH07508648A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP6502006A 1992-06-25 1993-06-15 ワクチンとしての即時型ｈｓｖ−２ウイルスタンパク質ｉｃｐ２７ Pending JPH07508648A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9213559.9 1992-06-25
GB9213559A GB9213559D0 (en) 1992-06-25 1992-06-25 Vaccines
PCT/EP1993/001525 WO1994000575A1 (en) 1992-06-25 1993-06-15 Immediate early hsv-2 viral protein icp27 as vaccine

Publications (1)

Publication Number Publication Date
JPH07508648A true JPH07508648A (ja) 1995-09-28

Family

ID=10717757

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6502006A Pending JPH07508648A (ja) 1992-06-25 1993-06-15 ワクチンとしての即時型ｈｓｖ−２ウイルスタンパク質ｉｃｐ２７

Country Status (11)

Country Link
EP (1) EP0649470A1 (enExample)
JP (1) JPH07508648A (enExample)
KR (1) KR950702244A (enExample)
CN (1) CN1092812A (enExample)
AU (2) AU676166B2 (enExample)
CA (1) CA2138996A1 (enExample)
GB (1) GB9213559D0 (enExample)
MX (1) MX9303771A (enExample)
NZ (1) NZ253138A (enExample)
TW (1) TW269635B (enExample)
WO (1) WO1994000575A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007505147A (ja) * 2003-09-12 2007-03-08 アンティジェニクス インコーポレーテッド 単純ヘルペスウイルス感染の治療および予防用ワクチン
JP4768121B2 (ja) * 1998-02-05 2011-09-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｍａｇｅファミリーからの腫瘍関連抗原及びそれらをコードする核酸配列、融合タンパク質の及びワクチン接種のための組成物の調製のための使用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69941703D1 (de) * 1999-10-11 2010-01-07 Pasteur Institut Lentivirale Vektoren für die Herstellung von immunotherapeutischen Zusammensetzungen
US7196066B1 (en) 1999-11-03 2007-03-27 Powderject Vaccines, Inc. DNA-vaccines based on constructs derived from the genomes of human and animal pathogens

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4768121B2 (ja) * 1998-02-05 2011-09-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｍａｇｅファミリーからの腫瘍関連抗原及びそれらをコードする核酸配列、融合タンパク質の及びワクチン接種のための組成物の調製のための使用
JP2007505147A (ja) * 2003-09-12 2007-03-08 アンティジェニクス インコーポレーテッド 単純ヘルペスウイルス感染の治療および予防用ワクチン

Also Published As

Publication number Publication date
GB9213559D0 (en) 1992-08-12
WO1994000575A1 (en) 1994-01-06
AU676166B2 (en) 1997-03-06
CN1092812A (zh) 1994-09-28
KR950702244A (ko) 1995-06-19
TW269635B (enExample) 1996-02-01
CA2138996A1 (en) 1994-01-06
MX9303771A (es) 1994-05-31
AU4326493A (en) 1994-01-24
AU1785597A (en) 1997-06-19
NZ253138A (en) 1995-10-26
EP0649470A1 (en) 1995-04-26

Similar Documents

Publication Publication Date Title
JP3247376B2 (ja) 弱毒化され、遺伝子的に加工されたシュードラビーウイルスｓ−ｐｒｖ−１５５およびその使用
JPH06506705A (ja) 再発性ｈｓｖ感染用の免疫療法
CN113201507B (zh) 一种重组的伪狂犬病病毒及其疫苗组合物
JPH084508B2 (ja) 組み換えワクチニアウイルス
JPH10500281A (ja) 非病原性ｈｉｖ−１種
JPH11308998A (ja) 単純ヘルペスウイルスのｖｐ１６のワクチン
WO1995016779A9 (en) Herpes-symplex-virus type 2 icp4 protein and its use in a vaccine composition
Aguillón et al. Tc45, a dimorphic Trypanosoma cruzi immunogen with variable chromosomal localization, is calreticulin.
US10201604B2 (en) Live attenuated infectious laryngotracheitis virus (ILTV) vaccines and preparation thereof
CN112159480A (zh) 一种鸡传染性法氏囊病病毒多抗原表位蛋白及其应用
JPH07508648A (ja) ワクチンとしての即時型ｈｓｖ−２ウイルスタンパク質ｉｃｐ２７
Epstein Vaccination against Epstein-Barr virus: current progress and future strategies
JP2025137897A (ja) 新規なネコヘルペスウイルスワクチン
JPH02500327A (ja) マイコバクテリアに対する遺伝子操作ワクチン
CN106967174A (zh) 多肽融合蛋白gwp在抗立氏立克次体的免疫保护中的应用
KR102935883B1 (ko) 제3 유전자형 e형 간염 바이러스 캡시드 단백질의 면역원성 단편 또는 이의 바이러스-유사 입자를 포함하는 e 형 간염의 예방 또는 치료용 백신 조성물
US8465748B2 (en) Vaccine compositions and methods containing an immunogen derived from equine arteritis virus
Grausz et al. Messenger RNA extracted from Schistosoma mansoni larval forms codes for parasite antigens when translated in vitro
CN1035126A (zh) 编码狂犬病毒糖蛋白的基因片段及用此片段制备狂犬病毒糖蛋白的方法
CN111676244B (zh) 以麻疹病毒为载体的麻疹、风疹联合疫苗
JPH06505865A (ja) トキソプラズマ・ゴンディの蛋白抗原のクローニング及び発現
CA2407036A1 (en) A nucleic acid construct encoding a processing component derived from the n-terminal region of the hepatitis virus orf2, and an antigenic polypeptide
JPH07265093A (ja) 哺乳動物細胞を用いる日本脳炎ウイルス表面抗原蛋白質の製法
CN1222393A (zh) 疫苗组合物及其制备方法
KR102935884B1 (ko) 제4 유전자형 e형 간염 바이러스 캡시드 단백질의 면역원성 단편 또는 이의 바이러스-유사 입자를 포함하는 e 형 간염의 예방 또는 치료용 백신 조성물